Sort by
Relevancy
1 - 20 out of 8910 Results 8910 ResultsSelect All
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Triplet chemotherapy with CF plus docetaxel (DCF) improved survival compared to CF as a neoadjuvant treatment for locally advanced esophageal squamous cell cancer (ESCC) based on the result from JCOG1109 (jRCTs031180202). Here we report results with 5 years minimum follow-up.
Abstract: 4082 | Poster Bd #: 62
Presenter:
Ken Kato MD, PhD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Head and neck cancers (HNC) consist of a group of biologically and clinically diverse malignancies. Oral cavity squamous cell carcinoma (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC) are the most common subtypes, together comprising the majority of HNC cases. While these cancers are associated with tobacco use and alcohol consumption, infection with human papilloma virus (HPV) is also etiologic to HNC, with OPSCC known to harbor higher HPV positivity (HPV+) rates relative to OCSCC, which is largely HPV-negative (HPV-). This distinction is clinically relevant as HPV+ tumors are more responsive to therapy and associated with better prognosis. While early-stage OCSCC/OPSCC has 5-year survival rates of >80%, diagnosis typically occurs at advanced stages, where the survival rate drops to 20-40%. Compounding this grim outlook is the growing incidence in patients that do not smoke or drink alcohol, as well as the startling rise in HPV+ OPSCC cases, thus increasing the affected population and burden on the healthcare system. Currently, painful incisional biopsies are the standard method to diagnose HNC, and there are no accepted non-invasive screening options for early disease detection or serial assessment of treatment efficacy. There is an urgent need for non-invasive diagnostic solutions that accurately identify disease at an early stage and quickly discern HPV status to inform effective treatment decisions and improve patient outcomes.
Abstract: 6057 | Poster Bd #: 373
Presenter:
Evgeny Izumchenko, PhD, MSc
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Pancreatic cancer patients treated with FOLFIRINOX often suffer from severe neutropenia leading to dose reductions and sometimes fatal outcomes. However, there is no high-level evidence for primary prophylaxis of peg-GCSF for those patients. We report the result of a multi-institutional, open-label, randomized phase II trial of the peg-GCSF for unresectable pancreatic cancer patients treated with first-line modified-FOLFIRINOX.
Abstract: 4145 | Poster Bd #: 125
Presenter:
Choong-kun Lee, MD, PhD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Early detection of breast cancer is crucial for improved patient outcomes but cannot always be achieved through mammography for the more than 40% of women with dense breast tissue (BI-RADS C & D). Breast density masks the appearance of tumors, reducing mammographic sensitivity, which can result in false negatives and delayed diagnosis. Orphan non-coding RNA (oncRNAs) are a novel category of small RNAs that are present in tumors and largely absent in healthy tissue. We have recently demonstrated that oncRNAs secreted from breast cancer cells into the bloodstream enable early detection of breast cancer with high sensitivity and specificity. Here, we examine whether these oncRNAs are unaffected by breast tissue density, making them an effective blood-based biomarker in women with dense breast tissue.
Abstract: 3065 | Poster Bd #: 210
Presenter:
Jeremy Ku, PhD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
The data presented here is from a multicenter, randomized, open-label, controlled Phase III clinical study evaluating the feasibility of short-course radiotherapy (shortRT) sequentially combined with camrelizumab and chemotherapy as neoadjuvant therapy (NAT) for locally advanced rectal cancer (LARC)(UNION). Our aim is to explore the value of circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) in assessing the comparative efficacy of short-course and long-course chemoradiotherapy (CRT).
Abstract: LBA3606 | Poster Bd #: 269
Presenter:
Zhenyu Lin, FASCO
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
OUTBACK was an international multi-center phase 3 trial investigating adjuvant chemotherapy following definitive chemoradiation in locally advanced cervix cancer. We analysed if baseline characteristics were associated with survival outcome. More specifically, we determined whether race held prognostic significance relative to established clinical factors.
Abstract: 1594 | Poster Bd #: 465
Presenter:
Yeh Chen Lee, FRACP, MBBS, MPhil
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Pancreatic ductal adenocarcinoma (PDAC) is one for the most lethal types of cancer. Nearly 80% of the PDAC patients are diagnosed at advanced unresectable stages. Therefore, an accurate early diagnosis assay is urgently needed for reducing PDAC related mortalities. In this study, we aim to utilize cfDNA fragmentomics and machine learning techniques for sensitively detecting PDAC patients.
Abstract: 4173 | Poster Bd #: 153
Presenter:
Lingdi Yin
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Despite improvements, patients with advanced cancer often do not receive goal-concordant care at the end of life (EOL). Challenges with prognostication contribute to delays ACP conversations and result in more aggressive care, gaps in symptom management, and hospice underuse. Early identification of patients at high risk for mortality provides an avenue to implement targeted ACP conversations.
Abstract: 1552 | Poster Bd #: 423
Presenter:
Mihir Patel
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Cervical Cancer is still significant cause of mortality and morbidity among females in India. Various methods of cancer screening are currently practiced for cervical cancer prevention including human papilloma virus (HPV) screening, pap smear, visual inspection with Lugol’s iodine (VILI), visual inspection with acetic acid (VIA) etc. The success of any cancer screening method is based on the feasibility of large-scale implementation at community level and the scientific validity of the screening test. VIA/VILI has been proven to prevent mortality in cervical cancer. This study is based on analysis of prospectively maintained database of community based cervical cancer screening using VIA/VILI in northern Kerala from 2002 to 2020.
Abstract: 10550 | Poster Bd #: 77
Presenter:
Krishnanadha Pai, BSc, BA
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Cancer stands as the 2nd leading cause of deaths and disability in the United States (US), and among the numerous contributing factors, modifiable risk factors play a significant role in exacerbating this burden. Within the spectrum of cancers, alcohol consumption ranks as the second leading attributable cause of death, as per the Global Burden of Disease Cancer Attributable Risk Factor Study.
Abstract: 10575 | Poster Bd #: 102
Presenter:
geethika chandra potluri, MBBS
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Biliary tract cancers are rare with the majority of pts diagnosed with metastatic disease at initial presentation. Up to 20% of pts will have peritoneal metastases, resulting in symptoms of ascites, abdominal pain, and potential bowel obstruction. Despite advances in standard of care systemic treatments such as combination gemcitabine, cisplatin, and durvalumab (gem/cis/durva), penetration to peritoneal metastases may be poor. While addition of nab-pacl*taxel to gem/cis increased objective response in a phase 2 study (1), SWOG 1815 did not demonstrate a significant improvement in survival with the triplet combination compared to gem/cis (2), possibly due to added toxicity. PIPAC directly delivers treatment to the peritoneal space, which could potentially reduce toxicity and improve efficacy. We aim to investigate the safety of PIPAC nab-pacl*taxel plus systemic gem/cis/durva in biliary tract cancer pts with peritoneal metastases.
Abstract: TPS4186 | Poster Bd #: 163a
Presenter:
Daneng Li MD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Multiple myeloma (MM) is the most common type of plasma cell cancer in the U.S. MM is consistently proceeded by monoclonal gammopathy of undetermined significance (MGUS). Studies have identified several risk factors for the progression of MGUS to MM. However, the contribution of each of these risk factors has not been quantified. We computed the population attributable fractions (PAFs) for selected risk factors in the U.S. Veterans Health Administration (VHA) health system.
Abstract: 7552 | Poster Bd #: 189
Presenter:
Su-Hsin Chang PhD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Tislelizumab (TIS), an anti-programmed cell death protein 1 (PD-1) antibody, demonstrated improved anti-tumor response and tolerable safety in patients (pts) with previously treated, locally advanced unresectable or metastatic microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumors, including colorectal cancer (CRC; NCT03736889). Recent studies of other anti-PD-1 antibodies indicate potential clinical benefit of neoadjuvant anti-PD-1 therapy in pts with resectable MSI-H/dMMR CRC. Here, we report efficacy and safety outcomes of neoadjuvant TIS from a multicenter phase II trial (NCT05116085) in this population.
Abstract: 3599 | Poster Bd #: 262
Presenter:
Ke-Feng Ding MD, PhD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
The efficacy of third line and subsequent treatments for advanced colorectal cancer (mCRC) is suboptimal, and the available drug options are limited. Approximately 95% of mCRC patients belong to the type of satellite stability (MSS), which often shows poor response to single immunotherapy. Previous clinical trials have preliminarily demonstrated that the potential application of combining anti-angiogenesis drugs with immune checkpoint inhibitors (ICIs) in mCRC. Chidamide is an isoform selective inhibitor of histone deacetylase (HDAC). Studies have shown its synergistic effect with PD-1 monoclonal antibody in anti-tumor activity. Therefore, we aim to conduct further investigations centered on the combination of Chidamide+Serplulimab+standard third-line treatments in mCRC.
Abstract: TPS3637 | Poster Bd #: 296b
Presenter:
Wei Li
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
CDKN2A encodes the inhibitor of the cyclin-dependent kinases p16 and is frequently methylated in colorectal cancer, thus reducing the exp levels of p16 protein. In pre-clinical models of colorectal cancer cells, the demethylation of CDKN2A gene induces topoisomerase I upregulation increasing the sensitivity to irinotecan. In metastatic colorectal cancer (mCRC) pts, the role of p16 expression has been poorly investigated.
Abstract: 3562 | Poster Bd #: 225
Presenter:
Marco Maria Germani MD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Timely and efficient accrual to oncology treatment trials is among the most vital components of clinical research. However, more than 80% of trials fail to reach enrollment targets, compromising outcome interpretation and cost. We hypothesized that a noveland customized application of adult-learning methods would enhance clinical trial screening and randomization.
Abstract: 11025 | Poster Bd #: 220
Presenter:
Matthew Burke
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Integra Connect previously created in-patient (IP) admission prediction model based on OCM data. One of the challenges for practices in a value-based care (VBC) program is to provide continuous care-coordination during and after an IP admission. Our objective is to show how adopting combination machine learning (ML) models can predict IP length of stay (LOS). Potential benefits include an overall reduction in LOS which could minimize the risk of hospital acquired conditions.
Abstract: 11084 | Poster Bd #: 279
Presenter:
Srisairam Achuthan PhD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
Leukemia is a cancer of the blood and bone marrow characterized by the rapid and uncontrolled production of abnormal white blood cells. Acute myeloid leukemia (AML) makes up 15–20% of all childhood acute leukemias (1). The purpose of this study is to use the National Cancer Database (NCDB) to provide an updated investigation of racial disparities in survival in pediatric patients with AML. Investigating the different factors associated with poor outcomes provides valuable information when allocating resources and understanding where policies will be useful to improve patient outcomes.
Abstract: 10031 | Poster Bd #: 398
Presenter:
Ashley Becker
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
In the US, disparities in lung cancer mortality exist for African American, Hispanic, and other minorities. Standard of care low dose CT screening (LDCT) detects early-stage disease and improves mortality, yet disparities are perpetuated in screening by eligibility criteria derived from cohorts underrepresenting these minorities. One such cohort is the National Lung Screening Trial (NLST) cohort which is 92% White. Consequently, guidelines for lung cancer screening may be insufficient to address the unique needs of diverse populations. We hypothesize that Artificial Intelligence prediction of future lung cancer risk from an individual’s LDCT can partially mitigate racial and ethnic disparities and improve health system practice guidelines by individualizing screening risk as compared to current general guidelines. Here, we benchmark a Resnet18 3D neural network trained on NLST LDCT images, Sybil, on the diverse patient population of the University of Illinois Health system (UIH) which is 20% White and 60% African American.
Abstract: 1584 | Poster Bd #: 455
Presenter:
Abdul Zakkar, MD
Abstracts & Presentations
2024 ASCO Annual Meeting - Poster Session
BRAF V600E mutations are present in 8-12% worldwide of patients with metastatic colorectal cancer (mCRC) and linked with a poor prognosis. Encorafenib + cetuximab (E+C) was approved by the FDA and EMA for patients with BRAF V600E-mutant mCRC who received prior systemic therapy, based on data from the BEACON CRC study.
Abstract: LBA3559 | Poster Bd #: 222
Presenter:
Lin Shen, MD
Items per page